SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending due to the approval of its merger with Strive Enterprises, paving the way for a Bitcoin treasury company. The community is excited about the potential for a short squeeze, with some drawing comparisons to other high-flying crypto plays. With potential access to significant capital post-merger, discussions are centered around the stock's potential valuation and ability to outperform Bitcoin itself.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to a surprise announcement of a warrant dividend for shareholders, sparking discussions around share lending and potential for a short squeeze. The community is analyzing the implications of these warrants, particularly how they may impact shorts and the stock's price movement. Positive earnings are adding fuel to the fire, with many expecting significant price swings.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is trending following its earnings report, despite missing estimates, due to strong forward guidance and significant growth in cloud infrastructure revenue, particularly from multi-cloud databases. The community is focused on the company's massive backlog and potential for future growth in the AI space, leading to a debate about whether the stock's surge is justified or if it's a sign of a market bubble. Discussions also revolve around the potential impact on other tech stocks and Oracle's position in the cloud computing sector.

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

QMMM is trending due to a massive short squeeze following news of a new crypto treasury strategy, leading to extreme volatility and significant gains for some traders. Community discussions revolve around the potential for continued upward momentum versus an imminent pullback, with comparisons to other high-flying stocks in the sector. Speculation abounds regarding market manipulation and the risks associated with China-based stocks.

CaliberCos, Inc. operates as an asset management firm. It provides various support services including asset management & fund set-up services, as well as lending support, construction & development management, and real estate brokerage services. The company was founded by John Christopher Loeffler II and Jennifer Schrader in January 2009 and is headquartered in Scottsdale, AZ.

CaliberCos Inc - Ordinary Shares - Class A

CaliberCos Inc 

CWD is trending due to recent volatility, with community members discussing a potential pump and dump following the company's announcement of purchasing Chainlink tokens. Concerns about possible scams, dilution, and dark pool activity are circulating, while others hope for a short squeeze and recovery. The stock's dramatic price swings are drawing attention, with comparisons to other volatile stocks in the crypto space.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending amid growing investor interest in AI and e-commerce, with discussions around its potential for high growth and comparisons to other AI companies. The community is actively debating entry points, holding strategies, and the impact of upcoming earnings, while also highlighting the company's partnerships and patented technology. Some are expressing concerns about dilution and short selling, while others are very bullish for a run to double digits.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors discuss its upcoming earnings report and the potential impact on the stock's valuation, with the community weighing positive analyst sentiment against concerns about profitability. A key point of discussion revolves around the company's position in the cybersecurity sector relative to competitors and potential for long-term growth. Some traders are also focused on short-term strategies, anticipating volatility around the earnings release.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the following segments: Design Automation, Design IP, and Software Integrity. The Design Automation segment includes silicon design, verification products and services, system integration products and services, digital, custom, and FPGA IC design software, verification software and hardware products, and manufacturing software products. The Software Integrity segment includes a solution for building security and compliance testing into the customers' software development lifecycle and supply chain. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys is trending due to mixed reactions to its recent earnings report and future outlook, with investors focused on the company's exposure to macro uncertainties and the potential impact of its pending acquisition of Ansys. While some community members express confidence in the company's long-term prospects and AI-driven growth, others are concerned about the conservative guidance and its effect on the stock's valuation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as the community reacts to the unveiling of the new iPhone 17 lineup and other product updates. Discussions revolve around the perceived lack of groundbreaking innovation, with some expressing disappointment and others highlighting the potential of features like the translation-enabled AirPods. Many traders are anticipating a post-event dip, while others suggest that the company's history points to a potential rally after the initial sell-off.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Foghorn Therapeutics Inc. (FHTX) have performed compared to their sector so far this year.

Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Are Medical Stocks Lagging  Arcutis Biotherapeutics (ARQT) This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates

Arcutis Biotherapeutics Inc.'s stock jumped 8.7% in after-hours trading on Tuesday following a stronger-than-expected fourth-quarter performance, driven by surging demand for its flagship inflammatory dermatology treatment.&nbsp;The upbeat results ignited a sharp rise in retail investor engagement, with message volume on Stocktwits soaring nearly 430% and sentiment shifting from ‘neutral’ to ‘bullish’ within a day.<figure class="image"><img style="aspect-ratio:1266/724;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ARQT_message_volume_meter_as_of_Feb_25_2a89fcb8eb.png" alt="ARQT message volume meter as of Feb 25.png" width="1266" height="724"><figcaption>ARQT message volume meter as of Feb 25 | source: Stocktwits</figcaption></figure>The company reported a fourth-quarter loss per share of $0.09, significantly better than the anticipated loss of $0.26.&nbsp;Revenue hit $71.4 million, well above the consensus estimate of $60.52 million.&nbsp;Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.CEO Frank Watanabe attributed the company's strong momentum to a well-executed pricing and access strategy and the successful commercial launch of two new Zoryve indications in 2024.Retail investors reacted enthusiastically, with one user calling the earnings report a "10/10 release."&nbsp;<stembedurl>https://stocktwits.com/Dilly_Poppins/message/605742985</stembedurl>Another investor speculated that given Zoryve's rapid growth and multiple indications, Arcutis could become an attractive acquisition target for larger biopharma companies.<stembedurl>https://stocktwits.com/lyonsa14/message/605727827</stembedurl>Chief Commercial Officer L. Todd Edward said the company plans to introduce a new foam formulation of Zoryve for body and scalp psoriasis in the second half of the year. A pediatric label expansion is also in the pipeline.&nbsp;He highlighted strong Medicaid coverage and ongoing Medicare Part D negotiations as key factors that could help Arcutis deepen its market penetration.The company said it ended 2024 with $228.6 million in cash and marketable securities and has significantly reduced interest expenses after repaying $100 million in debt in October.&nbsp;Arcutis reaffirmed its target of reaching cash flow break-even in 2026.According to Koyfin data, short interest in the stock last stood at 16.2%, down from 19.7% at the beginning of the year. Despite the after-hours rally, Arcutis shares are down more than 14% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.

Equity

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.


Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a 'Clear Win for Your Skin' Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a 'Clear Win for Your Skin' PR Newswire...

Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts

Latest Ratings for ARQT
 DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsOverweight Nov 2021Morgan StanleyMaintainsOverweight Jul 2021Morgan StanleyMaintainsOverweight
 View More Analyst...

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Current Price	$17.93
Prev Close	$17.33
Open	$17.23
Dividend Yield	0.00%
50-Day Moving Average	$15.13
Beta	1.26
Avg. Volume	1.73M
PE Ratio	-23.28

52-Week High	$17.75
52-Week Low	$8.03
Market Capitalization	$2.08B
EPS (Annual)	-$1.16
Price to Book	14.94
Revenue Per Employee	$574,684.21
Enterprise Value/EBITDA	N/A

ARQT
Arcutis Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARQT News

ARQT Arcutis Biotherapeutics Inc